Skip to content
TrialMatch
Sign up
Recruiting Phase 2

Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma

Create a profile to match View the full record on ClinicalTrials.gov

About this study

The purpose of this research is to evaluate the addition of radiotherapy to the standard immunotherapy drugs that are given to patients with advanced or metastatic melanoma that has spread to other parts of the body. Radiotherapy uses x-rays to target and kill melanoma cells and immunotherapy works by activating the body's own immune system to seek out and fight melanoma cells. Both of these treatments are commonly given to patients with advanced melanoma and other cancers. Both treatments are usually given separately but can also be given together. The aim of this research is to find out if giving radiotherapy and immunotherapy together is better than giving immunotherapy alone. The type of radiotherapy to be used in this project is known as 'stereotactic' body radiotherapy or SBRT (also known as stereotactic body ablative radiotherapy, SABR). SBRT targets the radiation very precisely at the metastatic deposits in the body. This method protects the healthy areas near the melanoma. SBRT works by delivering a high dose of radiation precisely to the areas of melanoma which causes the melanoma cells to break apart and eventually die. SBRT is given in 'fractions' which means the high dose is given in small measures over several days, depending on the number and size of metastases.

Condition
Melanoma Metastatic
Tested
Stereotactic Body Radiotherapy (extracranial) concurrent with Immunotherapy, Immunotherapy alone
Sponsor
Melanoma Institute Australia

Who can join

Age
18 years and older
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 14

  • Minimum age: 18 years
  • Study condition: Melanoma Metastatic
  • Female or male patients, age 18 or older
  • Willing to provide signed informed consent
  • Life expectancy \> 6 months
  • First presentation of AJCC Stage IV (any N, M1a, M1b, M1c), histologically confirmed cutaneous, acral or unknown primary melanoma with one to five extracranial metastases detected on CT and whole body PET-CT, and considered unresectable
  • A primary lesion and / or up to 4 in-transit metastases(is) (ITM) in addition to distant metastases(is) are permitted and will be counted in the maximum number of permitted baseline lesions
  • Prior surgery for symptomatic disease (e.g. small bowel obstruction) for this first presentation of Stage IV melanoma is permitted, provided the total number of remaining extracranial metastases is ≤ 5 (NOT including the resected lesion). No more than one excised metastatic lesion is permitted
  • At least one metastasis should be measurable as a target lesion per RECIST version 1.1
  • No evidence of cerebral metastases on MRI brain (CT brain is acceptable if there is contraindication to MRI)
  • All lesions can be treated with a minimum SBRT biologically effective dose (BED) of 48Gy
  • Able to tolerate treatment with immunotherapy as determined by the medical oncologist
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days of randomisation

Exclusion 10

  • Ocular or mucosal melanoma
  • Serious or unstable medical co-morbidities or other conditions that could interfere with the patient's safety, consent, or compliance
  • Patients for whom there is a definite and immediate indication for radiotherapy (e.g., spinal cord compression, rapidly progressing disease associated with clinical signs and symptoms)
  • Prior radiotherapy for Stage IV disease (prior adjuvant radiotherapy to primary site or nodal field (Stage I-III disease) is permitted, however adjuvant-treated sites must not be included in the baseline lesions
  • Inability to treat all disease sites with SBRT as determined by radiation oncologist
  • Prior systemic drug therapy for melanoma, unless given in the neoadjuvant or adjuvant setting for Stage I-III disease
  • Any contraindication to the planned standard of care immunotherapy regimen per regulatory approved product information
  • For patients with liver metastases - moderate/severe liver dysfunction
  • A known history of another malignancy or concurrent malignancy unless the patient is disease-free for a minimum of 1 year, is completely treated and is at low risk of recurrence
  • Pregnant or breastfeeding females

Where

5 sites, 5 recruiting

The Alfred Hospital

Melbourne, Victoria, Australia

Recruiting

Westmead Hospital

Westmead, New South Wales, Australia

Recruiting

Melanoma Institute Australia

Wollstonecraft, New South Wales, Australia

Recruiting

Princess Alexandra Hospital

Woolloongabba, Queensland, Australia

Recruiting

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.